|
J Biol Chem, Vol. 274, Issue 46, 32847-32854, November 12, 1999
Biotin Protein Ligase from Saccharomyces
cerevisiae
THE N-TERMINAL DOMAIN IS REQUIRED FOR COMPLETE ACTIVITY*
Steven W.
Polyak,
Anne
Chapman-Smith,
Peter J.
Brautigan, and
John
C.
Wallace
From the Department of Biochemistry, University of Adelaide,
Adelaide, South Australia SA 5005, Australia
 |
ABSTRACT |
Catalytically active biotin protein ligase from
Saccharomyces cerevisiae (EC 6.3.4.15) was overexpressed in
Escherichia coli and purified to near homogeneity in three
steps. Kinetic analysis demonstrated that the substrates ATP, biotin,
and the biotin-accepting protein bind in an ordered manner in the
reaction mechanism. Treatment with any of three proteases of differing specificity in vitro revealed that the sequence between
residues 240 and 260 was extremely sensitive to proteolysis, suggesting that it forms an exposed linker between an N-terminal 27-kDa domain and
the C-terminal 50-kDa domain containing the active site. The protease
susceptibility of this linker region was considerably reduced in the
presence of ATP and biotin. A second protease-sensitive sequence,
located in the presumptive catalytic site, was protected against
digestion by the substrates. Expression of N-terminally truncated
variants of the yeast enzyme failed to complement E. coli
strains defective in biotin protein ligase activity. In
vitro assays performed with purified N-terminally truncated
enzyme revealed that removal of the N-terminal domain reduced BPL
activity by greater than 3500-fold. Our data indicate that both the
N-terminal domain and the C-terminal domain containing the active site
are necessary for complete catalytic function.
 |
INTRODUCTION |
Biotin (vitamin H) is a protein-bound cofactor required for the
synthesis of functional biotin carboxylases and decarboxylases. These
enzymes catalyze essential metabolic processes in both prokaryotes and
eukaryotes using the biotin prosthetic group as a mobile carboxyl carrier (1, 2). The post-translational attachment of biotin to these
enzymes via the -amino group of a specific lysine residue is
catalyzed by biotin protein ligase
(BPL1; EC 6.3.4.15) in a
two-step reaction.
The best characterized BPL is the 35.3-kDa BirA protein from
Escherichia coli, which is a bifunctional protein that also acts as the repressor of the biotin biosynthetic operon (3, 4). The
crystal structure of the protein, determined at 2.3-Å resolution,
shows the domains identified from genetic and biochemical studies (4,
5). The N-terminal domain contains a helix-turn-helix fold for DNA
binding. The central domain, which contacts biotin and contains the
nucleotide triphosphate binding motif GRGRRG, is the catalytic domain.
No function has been assigned to the small C-terminal domain. BPL
protein (6-8) and the bpl gene (9, 10) have been isolated
from several other prokaryotes, and an increasing number of
birA homologues have been identified from genome sequencing
projects in organisms as diverse as Methanococcus jannaschii
(11) and Archaeoglobus fulgidus (12). Similarity with
E. coli BirA at the amino acid level suggests that all of these bacterial proteins are also bifunctional molecules with essentially the same domain structure.
Biotin-accepting enzymes can be recognized and biotinylated by BPL
derived from widely divergent sources (13-16), indicating that the
determinants of a functional protein/protein interaction have been
highly conserved throughout evolution. However, it is apparent that
eukaryotic BPLs, while catalyzing the same essential biotinylation
reaction, have different properties from the prokaryotic members of the
family. Most of the eukaryotic BPL proteins that have been purified are
around twice the size of the bacterial enzyme (reviewed in Ref. 17).
The gene for BPL from Saccharomyces cerevisiae encodes a
protein of 690 amino acids (predicted mass of 76.4 kDa (18)), and the
human enzyme is similar, containing 726 residues (15, 19). Plant BPLs
are intermediate in size between the bacterial and other eukaryotic
enzymes, with a molecular mass of 37-41 kDa (16, 20, 21). The
C-terminal region of the eukaryotic BPL sequences shows homology with
BirA and the biotin-binding protein, avidin, suggesting that this
contains the catalytic site. Residues in E. coli BirA
comprising the ATP-binding motif or residues that, if mutated, cause an
increased Km for biotin are all highly conserved
between species. Additionally, those residues shown to contact biotin
in the BirA crystal structure are invariant (15, 16, 18). Consistent
with biotin metabolism in the different organisms, none of the
eukaryotic proteins contains sequences that suggest any DNA binding activity.
While the large additional N-terminal domain present in both the human
and yeast BPL proteins shows some sequence similarity between the two
species (18), little is known of the function of this region of the
eukaryotic enzyme. Evidence for the functional importance of this
domain comes from the identification of mutations in human BPL
responsible for inherited metabolic disease, multiple carboxylase
deficiency. Of the known lesions giving rise to this neonatal onset
disorder, several point mutations alter residues in the vicinity of the
presumptive biotin binding site and give rise to a decreased affinity
for biotin (22, 23). However, other mutations, also responsive to
biotin in vivo, occur in the N-terminal domain (residues
215-240), some distance from the catalytic site (19, 22, 23). The loss
of BPL activity is apparently not due to either decreased affinity for
biotin or biotin-mediated stability (23), and it is not clear why the
defect responds to biotin therapy. Currently, no comprehensive
structural or functional data are available for the N-terminal region
of eukaryotic BPL.
Here we report the recombinant expression in E. coli of
active yeast BPL (yBPL) with a C-terminal hexahistidine tag. Limited proteolysis of the purified enzyme has confirmed predictions of the
domain structure based on sequence homology. Expression of N-terminally
truncated proteins indicated that the presence of both domains was
necessary for catalytic function.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Polyacrylamide was obtained from Bio-Rad;
nitrocellulose was from Schleicher & Schuell; restriction endonucleases
were purchased from New England Biolabs; Pwo DNA polymerase
was from Roche Molecular Biochemicals; Ni-NTA alkaline phosphatase
conjugate and Ni-NTA-agarose were from Qiagen; and
[3H]biotin (35 Ci/mmol) was from Amersham Pharmacia
Biotech. All reagents were of analytical grade or higher.
Oligonucleotides were purchased from Geneworks Ltd. (Adelaide,
Australia). The restriction sites in the oligonucleotides are indicated
by underlining, and the mutagenic changes are shown in boldface type.
The sequences of the oligonucleotides are as follows: Bpl5',
5'-CAACTATCATGAATGTATTAGTCTATAATGGC-3'; Bpl3', 5'-CCATTGTAGGGTCACCTTGAGC-3'; BplPst,
5'-TCAGAAAAGCTGCAGGCACTC-3'; BplBam,
5'-AAAGTCGGATCCTAATGATGATGATGATGATGACTCTGAACCTTTTTAGCAATTAAGC-3'; BplE233, 5'-ATCATACCATGGAAACCGTTGTGGAAAACCTG-3';
BplE369, 5'-ATCATACCATGGAATACTTCAAGTATCTGAATGTTC-3';
BplE409,
5'-ATATAACCATGGAAAGCACTTTACTTCACGTGGG-3'; BplPstBack, 5'-GAGTGCCTGCAGCTTTTCTGC-3'; AraFor,
5'-TGCCTGACGGTTTTTGCC-3'; AraFor2, 5'-AACTATGGCTGGAATGTCC-3'.
Nucleic Acid Manipulations--
Transformation, isolation of
plasmid DNA, restriction enzyme digestion, and agarose gel
electrophoresis were carried out using standard methods (24). All
nucleic acid constructs were confirmed by DNA sequencing using ABI
Prism Dye Terminator sequencing (Perkin-Elmer).
The plasmid pKS(bpl) was produced by ligating a 2.6-kilobase pair
BstBI/SnaBI DNA fragment, containing the Bpl
coding region, from pCY248 (18) into
AccI/SmaI-digested pBluescript
KS II. A 2.1-kilobase pair
NcoI/BamHI fragment, excised from pKS(bpl) and
containing the Bpl coding region from base pair +131 to the end of the
gene, was cloned into NcoI/BglII-digested pET16b
(Novagen), yielding the plasmid pN/B-Bpl. Subsequent cloning steps
introduced the 5' coding region and codons for six histidine residues
at the 3'-end of the gene. A BspHI site was introduced
around the initiation codon by polymerase chain reaction mutagenesis
using primers Bpl5' and Bpl3' with pKS(bpl) as template. This product was ligated into pGEM-T (Promega), and the 308-base pair fragment liberated by digestion of the resultant plasmid with BspHI
and BstEII was cloned into
NcoI/BstEII-treated pN/B-Bpl. This yielded the
expression vector pET(Bpl). Six histidine codons were introduced at the
3'-end of the gene by polymerase chain reaction mutagenesis using
primers BplPst and BplBam with pKS(bpl) as template. The expression
vector pET(Bpl-His) was constructed by a three-fragment ligation
containing the purified polymerase chain reaction product from this
reaction that had been treated with PstI/BamHI,
the 1.1-kilobase pair PstI/BamHI fragment from
pET(Bpl) and PstI-digested pET16b. The expression vectors
were transformed into the E. coli strain BL21( DE3)pLysS
(Novagen), and transformants were grown on Luria broth (24)
supplemented with 100 µg/ml ampicillin and 30 µg/ml chloramphenicol.
A vector was constructed to allow arabinose-inducible expression of
full-length yBPL with the C-terminal hexahistidine (His6) tag. The 2.1-kilobase pair NcoI/BamHI fragment
from pET(Bpl-His) was cloned into
NcoI/BglII-treated pAra13 (25), yielding
pN/B-Bpl-His. This construct was digested with NcoI and
BstEII and ligated to the 308-base pair
BspHI/BstEII fragment described above to yield p[Met1]Bpl 1-690-His6. Vectors for
expression of N-terminally truncated forms of yBPL were constructed by
introducing translation initiation codons, which also contained an
NcoI cloning site, preceding residues 233, 369, and 409 of
the full-length protein. Oligonucleotides Bpl233, Bpl369, or Bpl409
were included in separate polymerase chain reactions with
oligonucleotide BplPstBack and pKS(bpl) as the template. The purified
polymerase chain reaction products were digested with NcoI
and PstI and cloned into similarly treated pN/B-Bpl-His.
This gave constructs pAra[Met1]Bpl
233-690-His6, pAra[Met1]Bpl
369-690-His6, and pAra[Met1]Bpl
409-690-His6, respectively. All constructs were confirmed by DNA sequencing using oligonucleotides AraFor and AraFor2.
Bacterial Strains and Growth Media--
For large scale protein
production, the E. coli strain used was BL21( DE3), also
containing the plasmid pLysS (Novagen). The E. coli strains
used for complementation assays were the birA1 bioC strain,
CY918 (26) and the birA85 bioC strain BM4062 (27). Complementation was assayed on selective medium containing (per liter)
10 g of Bacto-tryptone, 0.5 g of yeast extract, and 5 g of NaCl (18), with growth scored after 16 h of incubation.
Nonselective medium for complementation was Luria broth (24).
Expression and Purification of Apo-yPC-104--
The construction
of a vector for expression of the C-terminal 104 residues of yeast
pyruvate carboxylase-1 (yPC-104) has been previously described (28).
Crude cell lysates containing both the apo and holo forms of yPC-104
were prepared using the method of Chapman-Smith et al. (26),
except cells were lysed in buffer A (50 mM Tris-HCl, pH
8.0, 0.1 mM EDTA). The lysate from 1 liter of culture was
filtered and passed through a Q-Sepharose column (Amersham Pharmacia
Biotech, 12 × 2.6 cm) equilibrated in buffer A, and the unbound
material containing apo-yPC-104 was collected. This flow-through
fraction was reapplied to the column and fractionated with a 250-ml
gradient from 0 to 200 mM NaCl in buffer A, run at 5 ml/min. Fractions containing apo-yPC-104 were pooled, concentrated, and
run on a Superdex-75 HR 10/30 (Amersham Pharmacia Biotech) gel
filtration column in 2 mM ammonium acetate, pH 7.5. Those fractions containing the purified apobiotin domain were lyophilized and
stored at 20 °C.
Expression of Yeast BPL and Preparation of Cell
Lysates--
Bacterial cultures of E. coli BL21( DE3)pLys
harboring pET(Bpl-His6) were grown in shake flasks in 2YT
supplemented with 100 µg/ml ampicillin and 30 µg/ml
chloramphenicol. Overnight cultures were diluted 1:100 into 2 liters of
fresh medium and grown at 30 °C to A600
0.6-0.8 before the addition of
isopropyl-1-thio- -D-galactopyranoside to a final
concentration of 0.1 mM. After 3 h, the cells were harvested by centrifugation and washed in binding buffer (20 mM Tris-HCl, pH 7.9, 0.5 M NaCl, 5 mM imidazole), and the pellet was stored at 80 °C
overnight. The cell pellet was thawed on ice in 60 ml of binding
buffer, with the addition of 1 mM phenylmethylsulfonyl fluoride, resulting in cell lysis by the action of T4 lysozyme expressed from the co-resident pLysS plasmid. The disrupted cell suspension was sonicated and centrifuged at 10,000 × g
for 10 min. After a second centrifugation, the supernatant was filtered through a 0.45-µm Minisart filter (Sartorius) prior to chromatography.
The expression and purification of the yBPL truncations were performed
essentially as above except that the truncations were expressed in
E. coli DH5 and induced by growth in media supplemented in 0.2% arabinose for 6 h at 30 °C. Before chromatography,
cells were disrupted by two passes through a French press
(82,800-103,500 kilopascals).
Purification of Yeast BPL--
His6-tagged material
was purified on a 2.5-ml Ni-NTA-agarose (Qiagen), gravity-fed column.
After loading the cell lysates onto the charged column equilibrated in
binding buffer, the column was washed with 12 column volumes of binding
buffer and 12 volumes of wash buffer (20 mM Tris-HCl, pH
7.9, 0.5 M NaCl, 10 mM imidazole), and bound
material was eluted with 6 volumes of elution buffer (20 mM
Tris-HCl, pH 7.9, 0.5 M NaCl, 0.5 M imidazole).
Fractions containing yBPL were pooled and dialyzed overnight against 4 liters of storage buffer (50 mM Tris-HCl, pH 8.0, 1 mM EDTA, 1 mM dithiothreitol, 5% (v/v)
glycerol). The BPL-containing fractions eluted from the nickel column
were further fractionated on a Q-Sepharose column (Amersham Pharmacia
Biotech; 12 × 2.6 cm) with a 450-ml gradient from 0 to 250 mM NaCl in storage buffer, run at 5 ml/min. Fractions containing yBPL, detected by SDS-PAGE and Ni-NTA Western blot, were
pooled and stored at 80 °C.
Assay of Yeast BPL--
BPL activity was assayed by measuring
the incorporation of [3H]biotin into either apoBCCP-87 or
apo-yPC-104 as described by Chapman-Smith et al. (29).
Briefly, the reactions contained 50 mM Tris-HCl, pH 8.0, 3 mM ATP, 5.5 mM MgCl2, 5 µM biotin, 5 pmol of [3H]biotin (specific
activity 35-44 Ci/mmol), 0.1 mM dithiothreitol, 0.1 mg/ml
bovine serum albumin, and either 20 µM apoBCCP-87 or 5 µM apo-yPC-104. The reaction was initiated by the
addition of purified yBPL to a final concentration of 13 nM, except where stated otherwise, and incubated at
37 °C for up to 30 min, when aliquots of the reaction were spotted
onto biotin- and trichloroacetic acid-treated filters. After air
drying, the filters were washed twice in 10% ice-cold trichloroacetic
acid and once in ethanol and dried, and the acid-insoluble
radioactivity was measured. A unit of BPL activity was defined as the
amount of enzyme required to incorporate 1 nmol of biotin per min.
Values for Km and Vmax were
determined by fitting a plot of substrate concentration against rate to
the Michaelis-Menten equation using GraphPad Prism for MacIntosh
(GraphPad Software Inc., San Diego, CA). In some experiments, to obtain
sufficiently high levels of radioactivity for accurate detection, it
was necessary to continue until greater than 10% of the limiting
substrate had been utilized. In this case, the data were transformed
for altering substrate concentration by the method of Lee and Wilson
(30) and plotted as transformed values s' and
v'.
Protein Techniques--
PAGE was carried out on 12%
polyacrylamide SDS gels with the Tris/glycine system (31), using Mark
12 wide-range protein standards (Novex). His6-tagged
protein was detected after Western transfer using Ni-NTA alkaline
phosphatase conjugate (Qiagen) following the manufacturers' protocol.
Quantitation of protein after PAGE was carried out by laser
densitometry, using a Molecular Dynamics model 300A densitometer with
ImageQuant software (Sunnyvale, CA), with adjustment for the effect of
molecular weight on Coomassie Blue staining. Protein concentration was
determined using the Bio-Rad protein assay kit. Electroblotting of
peptides onto polyvinylidene difluoride was performed as described by
Matsudaira (32). N-terminal sequencing of proteins by automated Edman
degradation was performed using a Perkin-Elmer Procise 492 protein sequencer.
 |
RESULTS |
Protein Expression and Purification--
The yeast bpl
gene was cloned into the pET expression vector for recombinant
expression in the E. coli strain BL21( DE3)pLysS, with the
hexahistidine tag on the C terminus to facilitate downstream purification of the enzyme (described under "Experimental
Procedures"). Assays for yBPL activity, carried out on crude lysates
from cells expressing the protein with and without the His6
tag, revealed that the presence of the His6 tag did not
affect the activity of the enzyme (data not shown). For optimal
recovery of active enzyme from the protein expression system, cells
were grown at 30 °C in shake flasks, and expression of yBPL was
induced with low concentrations of
isopropyl-1-thio- -D-galactopyranoside (0.1 mM). Initial experiments showed that growth at 37 °C and
higher isopropyl-1-thio- -D-galactopyranoside
concentrations led to inclusion body formation, in both shake flasks
and a 1-liter fermenter.
As an initial purification step, crude lysate was passed over a Ni-NTA
column, which gave a 30-40-fold enrichment (Table
I). Since His6-yBPL eluted
from the resin with only 20 mM imidazole, column washings
were performed under low stringency conditions (10 mM
imidazole). BPL activity was detected in the unbound material, but
since no His6-tagged protein was detected in this fraction by Western blot analysis, the activity apparently represented endogenous bacterial biotin ligase. The recombinant yBPL obtained by
Ni-NTA chromatography was immediately dialyzed overnight against storage buffer, since storage in imidazole resulted in irreversible inactivation of the enzyme. Additional purification using anion exchange chromatography was required following Ni-NTA chromatography, since the low stringency washing conditions failed to remove a number
of contaminating proteins (Fig. 1,
lane 2). After two chromatography steps, half of
the initial enzyme activity had been recovered, and the protein was at
least 80% pure. This represented a purification of around 88-fold
(Table I). However, in addition to the 77-kDa protein corresponding to
full-length His6-yBPL, a band of 50 kDa was observed on
SDS-PAGE of the pooled fractions from the Q-Sepharose column (Fig. 1,
lane 3). This protein was also detected on a
Ni-NTA blot, indicating the presence of the C-terminal His6
tag. N-terminal sequencing showed the 50-kDa protein to be a
proteolysis product of the intact yBPL, with cleavage occurring between
Lys-248 and Phe-249. The cleaved species and the intact protein also
co-eluted during hydrophobic interaction chromatography on
phenyl-Sepharose 6 resin and were only partially resolved by analytical
gel filtration on either Superdex 75 or 200 columns (Amersham Pharmacia
Biotech). Analysis by SDS-PAGE of this material after Superdex 75 fractionation demonstrated that the cleavage products did not remain
associated after three steps during the purification, since the 50- and
27-kDa fragments could be resolved by gel filtration (data not shown).
View this table:
[in this window]
[in a new window]
|
Table I
Purification of recombinant yBPL
Purification of recombinant yBPL from a 2-liter culture was performed
as described under "Experimental Procedures." The data given are a
representative example from three experiments. The units shown here are
nmol of holoprotein formed per min.
|
|

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 1.
Purification of recombinant yeast BPL.
The purification of yeast BPL was analyzed by SDS-PAGE. Fractions were
separated on a 12% polyacrylamide gel under reducing conditions.
Lane 1, 50 µg of crude extract; lane
2, 10 µg of material obtained from Ni-NTA chromatography;
lane 3, 5 µg of material obtained from the
Q-Sepharose step; lane 4, 5 µg of the protein
obtained after gel filtration. The migration of molecular mass markers
is indicated on the left.
|
|
In order to obtain a sample of intact yBPL that did not contain the
cleaved form, protein collected after anion exchange chromatography was
concentrated by ultrafiltration prior to fractionation on a preparative
Superdex 75 gel filtration column (26 × 600 mm; Amersham
Pharmacia Biotech) run in storage buffer. As the quantity of cleaved
yBPL constituted less than 20% of the sample (as determined by laser
densitometry of bands detected on SDS-PAGE), approximately 50% of the
intact enzyme in the sample was resolved away from the cleaved product
by collecting only the leading fractions of the protein peak. These
fractions contained full-length yBPL with a purity of greater than
95%, determined by SDS-PAGE (Fig. 1, lane 4) and
N-terminal sequencing. The intact yBPL purified in this way was used
for all subsequent kinetic and proteolysis analysis.
Biological Properties of yBPL--
The activity of yBPL was
determined by measuring the incorporation of [3H]biotin
into one of two biotin-accepting domains, either the C-terminal 87 amino acid residues of the E. coli biotin carboxyl carrier
protein (BCCP-87) (29) or the C-terminal 104 amino acid residues of
S. cerevisiae pyruvate carboxylase 1 (yPC-104) (28). Optimal
enzyme activity was observed at pH 8.0-8.5. The presence of magnesium
ions, ATP, biotin, and the apo form of a biotin domain were necessary
substrates for activity, and the addition of EDTA inhibited the
reaction. Other divalent metal ions could be used by yBPL, magnesium
(100%), calcium (109%), nickel (74%), and manganese (53%) ions
supporting activity to varying extents. However, cobalt (14%), zinc
(1.3%), and copper (0.5%) ions were a poor substitute for magnesium.
Inhibition of activity was observed in the presence of the monovalent
metal ions sodium and potassium at concentrations of 200 mM
(data not shown). The ability of the biotin analogues biocytin,
diaminobiotin, desthiobiotin, and iminobiotin to inhibit the enzyme was
investigated. At a concentration of 5 µM, none of these
analogues was able to inhibit the incorporation of 50 nM
[3H]biotin into acceptor protein. Furthermore, the
addition of lipoic acid (5 µM) or acetyl-CoA (5 µM) had no inhibitory effect on activity. Enzyme activity
was also completely dependent on ATP as the nucleotide source, since
substitution with UTP, GTP, and CTP gave 5.6, 0.6, and 0.4%,
respectively, of the activity observed with ATP.
Kinetic Analysis of yBPL--
The kinetic constants for
D-biotin, MgATP, and two different biotin domain
substrates, apoBCCP-87 and apo-yPC-104, were determined using steady
state kinetics (Fig. 2). The
Km for MgATP was determined to be 20.9 ± 3 µM (Fig. 2A). As has been observed with BPLs
from a wide variety of species, the yeast enzyme also had a low
Km for biotin; 67 ± 11 nM (Fig.
2B). The yeast substrate, apo-yPC-104, displayed a
Km of 1.0 ± 0.2 µM (Fig.
2C), whereas the Km for the bacterial
biotin domain was more than 10-fold higher (11.1 ± 1 µM; Fig. 2D).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 2.
Steady-state kinetic analysis of yBPL
substrate binding. The activity of yBPL-His was measured under
steady state conditions, which kept two substrates at constant,
saturating levels while varying the concentration of the third
substrate over the ranges indicated on the graphs. From the
curves, Km values for MgATP (A), biotin
(B), apo-yPC-104 (C), and apoBCCP-87
(D) were determined. The lines represent
nonlinear regression to the Michaelis-Menten equation using GraphPad
Prism, as described under "Experimental Procedures."
|
|
In order to determine the kinetically preferred order of addition of
substrates, we assayed the activity of yBPL under steady state
conditions when the concentrations of two substrates were varied while
maintaining the third at saturating levels. The double-reciprocal plots
from the velocity measurements are shown in Fig.
3. When biotin and MgATP were the varied
substrates, patterns of intersecting lines were obtained (Fig. 3,
A and B), indicating a reversible connection
between these two substrates in the reaction pathway (33). When the
concentration of acceptor protein was varied together with either
biotin or MgATP, patterns of parallel lines were observed on the
double-reciprocal plots (Fig. 3, C and D). These
results implied that both biotin and MgATP combine with yBPL before the
acceptor protein (33). Biotinyl-5'-AMP is known to react readily with
hydroxylamine to form biotinyl-hydroxamate (34, 35). When yBPL was
incubated with [3H]biotin, MgATP, and hydroxylamine,
[3H]biotinyl-hydroxamate was formed (data not shown),
confirming that the reaction pathway proceeds, as shown in Reaction 1, through the formation of the biotinyl-5'-AMP intermediate.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 3.
Steady-state kinetic analysis of yBPL ordered
substrate binding. Shown are double reciprocal plots of initial
velocities with variable biotin concentrations and different fixed
concentrations of MgATP, 50 µM ( ), 100 µM ( ), and 500 µM ( ) (A);
variable MgATP concentrations and different fixed concentrations of
biotin, 25 nM ( ), 50 nM ( ), and 70 nM ( ) (B); variable apo yPC-104 concentrations and
different fixed concentrations of biotin, 25 nM ( ), 35 nM ( ), and 50 nM ( ) (C); and
variable apo-yPC-104 concentrations and the different fixed
concentrations of MgATP as in A (D). Other assay
conditions were as described under "Experimental Procedures."
|
|
Since the formation of biotinyl-5'-AMP is accompanied by the release of
pyrophosphate, product inhibition studies with pyrophosphate were
performed. Pyrophosphate behaved as a competitive inhibitor relative to
MgATP and as a noncompetitive inhibitor with respect to biotin (Fig.
4), implying that MgATP binding precedes
biotin binding (33). Our data here are in agreement with a double
displacement kinetic mechanism for yBPL, where biotinylation proceeds
through two partial reactions. First, MgATP combines with the enzyme
prior to biotin binding, and the formation of biotinyl-5'-AMP is
accompanied by the release of pyrophosphate in a reversible reaction
(Reaction 1). Second, the enzyme-biotinyl-5'-AMP complex interacts with a biotin domain and catalyzes the transfer of the biotin moiety from
the adenylated intermediate onto acceptor protein. Biotin covalently
attached to the acceptor protein and MgAMP are released in the final
nonreversible step (Reaction 2).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 4.
Inhibition of yBPL activity with
pyrophosphate. Inhibition of yBPL activity by pyrophosphate was
subjected to Lineweaver-Burk analysis. Concentrations of pyrophosphate
included in the reactions were 0 µM ( ), 50 µM ( ), 100 µM ( ), and 500 µM ( ). A, double reciprocal plots of
initial velocity with varying MgATP and different fixed concentrations
of pyrophosphate. B, double reciprocal plots of initial
velocity with varying biotin concentrations and different fixed
concentrations of pyrophosphate. The ATP concentration was 0.5 mM. Other assay conditions were as described under
"Experimental Procedures."
|
|
Limited Proteolysis of yBPL--
Purified intact yBPL was
subjected to limited proteolysis with several proteases in order to
define the domain boundaries within the enzyme. The ligase was treated
with trypsin, chymotrypsin, and endoproteinase Glu-C for 2 h, and
the products were analyzed by SDS-PAGE (Fig.
5A). All three proteases
generated a fragment of about 50 kDa, which contained the C terminus,
identified using a Ni-NTA blot to probe for the His6 tag.
N-terminal sequencing of these products revealed that cleavage occurred
between Lys-256 and Thr-257 for trypsin, between Leu-254 and Thr-255
for chymotrypsin, and between Glu-243 and Ile-244 for endoproteinase
Glu-C (Fig. 5B). Digestion with both trypsin and
endoproteinase Glu-C released a second fragment containing the
His6 tag. These products, of approximately 27 kDa, were the
result of cleavage between Pro-408 and Glu-409 with endoproteinase
Glu-C and between Arg-425 and Gly-426 with trypsin. Since these
cleavage points are located around the predicted catalytic site, yBPL
was subjected to digestion after equilibration with saturating
concentrations of MgATP and biotin (Fig. 5A). Under these
conditions, the 27-kDa products were not detected, indicating that
cleavage did not occur at Glu-409 or Arg-425. In addition, cleavage at
Lys-256, Leu-254, and Glu-243 was considerably slower in the presence
of the substrates, since the release of the 50-kDa fragment was
markedly reduced in all cases. Together, these data imply that the yBPL
molecule contains two protease-sensitive sites, one within an
interdomain linker that connects a 27-kDa N-terminal domain with the
remaining 50 kDa of the protein and a second region within the
catalytic site. The enzyme-biotinyl-5'-AMP complex was more resistant
to proteolysis at both sites than yBPL alone, which suggested that
structural differences exist between the two enzyme forms, with the
enzyme complex having a more compact conformation.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 5.
Limited proteolysis of yBPL.
A, yeast BPL (1.8 µM) was treated with
endoproteinase Glu-C (lane 1), chymotrypsin
(lane 2), trypsin (lane 3),
or no protease (lane 4) at a protease:substrate
ratio of 1:100 (w/w) for 2 h at 37 °C. Proteases were
sequencing grade or higher (Roche Molecular Biochemicals). yBPL was
digested either with or without equilibrating the enzyme with 3 mM MgATP and 5 µM biotin prior to the
addition of protease, as indicated above the
lanes. Digestion was terminated by the addition of SDS
loading buffer and boiling for 5 min. Digestion products (3 µg/track)
were resolved on duplicate 12% polyacrylamide gels under reducing and
denaturing conditions. Total protein was visualized by Coomassie Blue
R250 staining (top), and the C-terminal His6 tag
was detected by Western transfer probed with Ni-NTA alkaline
phosphatase (bottom). The migration of molecular mass
markers is indicated on the left. B, the sequence
of yBPL in the protease-sensitive region between residues 240 and 260 is shown, with the cleavage points indicated by arrows. The
position of the peptide bond cleaved by an E. coli protease,
identified during purification, is also shown.
|
|
Tryptic digestion of either yBPL alone (apoenzyme) or yBPL-biotinyl-AMP
complex (holoenzyme) was performed, measuring both the loss of the
77-kDa intact protein and enzyme activity (Fig. 6A). As expected, the
holoenzyme was more resistant to proteolysis, and more enzyme activity
was retained, compared with apoenzyme (Fig. 6A). For both
enzyme forms, digestion of the enzyme and loss of activity occurred at
slightly different rates over the first 2 h, whereas with longer
reaction times the loss of activity corresponded to loss of intact
protein. This most probably reflects cleavage occurring at the two
protease-sensitive regions of the molecule determined above. Initially,
cleavage occurring in the interdomain linker was such that the digested
enzyme retained some activity, whereas proteolysis within the catalytic
domain inactivated the enzyme. Analysis of the products by SDS-PAGE
revealed that the loss of enzyme activity was indeed coincident with
the production of a 30-kDa fragment containing the His tag, the product of tryptic digestion in the active site (Fig. 6B).

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 6.
Analysis of tryptic digestion of yBPL.
A, yBPL-His was treated with trypsin, as described in Fig.
5, except the reactions were terminated by the addition of 0.3 µM aprotinin. The products of digestion over 4 h
were analyzed by SDS-PAGE (solid line) and
assayed for BPL activity (broken line). At each
time point, the amount of intact BPL or enzyme activity is shown as a
percentage of the initial starting material Error
bars, S.E. of at least three experiments. Prior to the
addition of trypsin, yBPL was preincubated in the absence ( ) or
presence ( ) of 3 mM MgATP and 5 µM biotin
at 37 °C for 5 min to form apo- or holoenzyme, respectively.
B, the formation of a 30-kDa fragment, containing the
C-terminal His6 tag, was analyzed by SDS-PAGE throughout
the tryptic digest of yBPL both in the presence (top) and
absence (bottom) of substrates. This fragment represents
cleavage at the ATP-binding site in yBPL.
|
|
In Vivo Characterization of Truncated yBPL--
A series of
vectors, for expression of N-terminally deleted forms of yBPL
containing a C-terminal His6 tag in E. coli,
were constructed as described under "Experimental Procedures."
These vectors, derived from pAra13 (25), expressed yBPL,
yBPL( 1-233), yBPL( 1-369), and yBPL( 1-409) under the control
of an arabinose-inducible promoter. All vectors were transformed into
the birA, biotin auxotroph strains CY918 (26) and BM4062
(27). These strains have a high requirement for biotin, and the
birA85 mutation in BM4062 also confers a
temperature-sensitive phenotype. Under selective conditions only those
strains expressing functional exogenous BPL survive, since the
essential E. coli enzyme acetyl-CoA carboxylase can be
biotinylated and is therefore active.
The CY918 strains bearing the expression vectors were grown on
permissive and selective media to test for complementation of the
defective bacterial birA1 (see "Experimental
Procedures"). Strains CY918 and CY918 harboring the parent expression
vector alone, pAra13, did not grow on the selective media supplemented with 0.2% arabinose, but growth was observed on nonselective media. The addition of as little as 3 nM biotin to the selective
media restored growth (data not shown). As expected, the strains
expressing either full-length yBPL or E. coli BirA, from
plasmid pCY216 (26) permitted growth on both media. However, expression
of the truncated forms of yBPL failed to complement the mutant strain
at either 30 or 37 °C on selective media (Fig.
7). For all truncations except yBPL( 1-409), an induced His6-tagged protein of the
expected molecular mass was detected in crude cell lysates using a
Ni-NTA blot, indicating that the proteins were being expressed (Fig.
8). Expression of yBPL-409 was not
detected, possibly because this truncation, which removes part of the
predicted catalytic region, is rapidly degraded.

View larger version (75K):
[in this window]
[in a new window]
|
Fig. 7.
Complementation of E. coli birA1
by truncated forms of yBPL. The E. coli strain
CY918 was transformed with vectors for arabinose-inducible expression
of N-terminal truncations of yBPL. Strains were grown on either
nonselective (A) or selective (B) media, as
described under "Experimental Procedures." Strains
1-4 expressed full-length yBPL, yBPL( 1-233),
yBPL( 1-369), and yBPL( 1-409), respectively.
|
|

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 8.
Expression of yBPL truncations in E. coli CY918. Whole cell lysates of E. coli
CY918 containing the vectors for arabinose-inducible expression of yBPL
truncations, were fractionated on a 12% polyacrylamide gel under
reducing conditions. The C-terminally His6-tagged proteins
were detected by Western transfer probed with Ni-NTA alkaline
phosphatase. The expressed proteins were yBPL (lane
1), yBPL( 1-233) (lane 2),
yBPL( 1-369) (lane 3), yBPL( 1-409)
(lane 4), and cells harboring pAra13
(lane 5). The migration of molecular mass markers
is indicated on the right.
|
|
The observed failure of the yBPL truncations to complement the
birA1 mutation at low concentrations of biotin may have been due to the truncated yeast enzymes themselves having a higher biotin
requirement, as has been reported for N-terminally truncated BirA (36).
Therefore, the complementation assay was carried out in a second
bacterial strain, BM4062 (27), where the endogenous bacterial BPL could
be heat-inactivated. At 42 °C, where the BirA85 protein was
nonfunctional (27), only full-length yBPL was able to sustain growth.
The assay was performed on media supplemented with increasing biotin
concentrations up to 1 mM. However, the additional biotin
did not permit the growth of strains expressing truncated yBPL.
In Vitro Characterization of Truncated yBPL--
The yBPL
truncations were expressed in E. coli DH5 cells and
partially purified by nickel chelating chromatography. The
Ni-NTA-purified material recovered from cells harboring pAra13
displayed no BPL activity, showing that endogenous bacterial BPL had
been removed. Full-length yBPL was found to have the highest specific
activity (25 nmol/min/mg; Fig. 9).
Removal of the N-terminal domain in construct yBPL( 1-233) was found
to reduce the activity of the enzyme by greater than 3500-fold (7 pmol/min/mg; Fig. 9). This truncation was further purified by anion
exchange chromatography and tested for activity in the presence of
increasing concentrations of biotin. The addition of up to 500 µM biotin in the reaction did not improve the enzyme's
activity (data not shown), suggesting the observed decrease in activity
for this truncation was not the result of an increased
Km for biotin, consistent with the in
vivo complementation assays. The truncation yBPL( 1-369) had
very low specific activity (1.7 pmol/min/mg). As expected, yBPL( 1-409), which has part of the proposed ATP binding motif deleted, showed no activity. It is evident that the 3500-fold reduction
in activity seen upon the deletion of the N-terminal domain reduced the
activity of yBPL to a level that is inadequate for viability.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 9.
In vitro activity assay of
truncated forms of yBPL. The truncated forms of yBPL were
expressed in E. coli DH5 , and the protein recovered after
Ni-NTA chromatography was assayed in the in vitro
biotinylation reaction, as described under "Experimental
Procedures."
|
|
 |
DISCUSSION |
Limited proteolysis of purified yBPL, undertaken to determine the
domain structure of the protein, indicated that the protein contained
two protease-sensitive regions, the more N-terminal of which lies
between residues 240 and 260. The observation that all three proteases
tested, as well as an endogenous E. coli protease, cut the
protein within this sequence suggests that this region most probably
forms an exposed linker sequence between a 27-kDa N-terminal domain and
the remaining 50-kDa portion of the protein. The second
protease-sensitive region we observed in yBPL occurred within the
50-kDa C-terminal region, which, based on sequence homologies, contains
the catalytic center (18). In fact, both the trypsin and endoproteinase
Glu-C-sensitive residues mapped in the putative ATP and biotin binding
region of the catalytic domain, with the trypsin cleavage site within
the proposed ATP binding motif, GRGRGG (18). These cleavage sites were
protected from proteolysis and subsequent loss of yBPL activity in the
presence of ATP and biotin (Figs. 5 and 6). Correspondingly, the
ligand-bound form of yBPL was more resistant to the loss of enzyme
activity that accompanied proteolysis than apoenzyme. These
observations strongly support the identification of the catalytic site
made from sequence homologies. In the crystal structure of the BirA, the region containing the ATP binding motif is one of several poorly
defined, solvent-exposed loops found close to the catalytic center (5).
A subtilisin-sensitive site lies within an unstructured loop adjacent
to the ATP binding loop, and cleavage is inhibited when either biotin
or biotinyl-5'-AMP is bound to the enzyme (37). We conclude that the
results of limited proteolysis presented here indicate that yBPL forms
two domains and that the cleavage observed around the ATP binding motif
suggests the presence of an exposed loop structure within the 50-kDa
C-terminal domain, as is seen in BirA.
In addition, and somewhat surprisingly, the presence of ATP and biotin
also reduced protease susceptibility within the proposed linker
sequence between the two domains. This suggests that substrate binding
caused a global conformational change, affecting sequences at some
distance from the binding site in the primary structure. Conformational
changes in BirA associated with substrate binding have also been
demonstrated (4). Interestingly, the N-terminal domain of BirA that is
involved in DNA binding appears to affect the affinity of the catalytic
domain for both biotin and biotinyl-5'-AMP. A truncation mutant in
which the N-terminal domain was absent was still able to catalyze
biotin transfer but displayed a 100-fold decrease in the affinity for
biotin and a 1000-fold decrease in the affinity for biotinyl-5'-AMP
(36). Biotin binding to this truncation caused no quenching of
intrinsic protein fluorescence, as opposed to the 15% quenching
observed with the intact enzyme (36). These data suggest that quenching
of fluorescence may be the result of the conformational changes that
are induced by biotin binding and that the truncated enzyme is
compromised in its ability to go through these changes. The interaction
between the DNA binding domain and the catalytic domain is accompanied by conformational changes and is thought to relate to repressor function of BirA (5). Our data indicate that although the N-terminal domain in yBPL has no equivalent DNA binding function, there is a
functional interaction with the catalytic domain.
Furthermore, expression of N-terminally truncated variants of yBPL in
two E. coli strains carrying birA mutations
showed that the presence of both domains was necessary to produce a
functional enzyme. Our analysis of the activity of the yBPL truncations
in vitro is consistent with the results of the
complementation assays, and it is evident that the 3500-fold reduction
in activity seen upon the deletion of the N-terminal domain reduced the
activity of yBPL to a level that is inadequate for viability. It is
likely that in the absence of the N-terminal domain conformational
changes associated with substrate binding, necessary for enzymatic
activity, may occur at a slower rate than in the presence of the domain and therefore affect the overall activity of the protein. This agrees
with the observation that tryptic cleavage of yBPL in the linker region
produced a form of yBPL that retained some catalytic activity in
in vitro assays (Fig. 6). While the precise role of the
N-terminal domain is unclear, the results presented here are consistent
with the studies of known defects in human BPL. Several point mutations
in the N-terminal domain of human BPL result in a defective enzyme (19,
22, 23), indicating that the integrity of this region of the protein is
important for function. Sequence homology between yeast and human BPL
in the N-terminal domain is low and allows different alignments, making
it difficult to precisely identify analogous residues and therefore to
produce point mutations in yBPL that mimic those isolated in the
defective human enzyme. However, these mutations in human BPL are found upstream of the protease-sensitive linker region in yBPL identified here (17), consistent with the inability of the N-terminal truncation yBPL( 1-233) to complement the birA defects. Structural
characterization of the N-terminal domain and the identification of
interactions with both the catalytic site and other molecules will aid
in determining the role of this domain in enzyme function.
While BPL has been purified from a variety of sources, the low
abundance of the enzyme has made purification of the endogenous enzyme
a difficult task. Since the availability of recombinant DNA technology
has permitted high level production of proteins in suitable hosts with
improved yields, protein overexpression has facilitated isolation of
BirA (38, 39) and Arabidopsis thaliana BPL from E. coli. Here we report recombinant expression in bacteria of a
eukaryotic member of this enzyme family. Cloning a hexahistidine tag
onto the C terminus of yBPL permitted the isolation of active enzyme in
a rapid two-step purification, with yields comparable with those
reported for recombinant production of the bacterial protein (38, 39).
Whereas partial purification of BPL from S. cerevisiae has
been reported previously (40), our system allowed purification to
apparent homogeneity (Fig. 1).
The results of our steady-state kinetic analysis of yBPL indicate that
biotinylation occurs through a two-step Bi Uni Uni Bi ping-pong
mechanism. In the first partial reaction, the enzyme complexes with ATP
and biotin and catalyzes the synthesis of biotinyl-5'-AMP with
subsequent release of pyrophosphate. The addition of the apo acceptor
protein then follows in the second partial reaction with the release of
the biotinylated protein and AMP. The kinetics of the formation of the
adenylated intermediate has been quantitatively analyzed using BirA
(41). The enzyme-biotinyl-5'-AMP complex is quite stable (41) and is
proposed to be the most abundant enzyme form in the cell. Here we
demonstrate that the precursors of the intermediate, ATP and biotin,
bind to yBPL in an ordered manner. As has been observed with plant BPL
(20), ATP binds to the yeast enzyme before biotin. This is in contrast
to the reaction pathway catalyzed by bacterial BirA, where biotin is the first ligand to bind the enzyme (41). The order of substrate binding in E. coli is believed to allow more responsive
regulation of biotin biosynthesis. When the cellular demand for biotin
is low, the BirA-biotinyl-5'-AMP complex occupies the bio
operator sequence and represses transcription of the biotin
biosynthetic operon. As apoBCCP levels increase, biotin is transferred
from the enzyme-bound adenylate to the protein-bound form, with
concomitant derepression of the biotin operon. Kinetic analysis of the
interaction of BirA with biotin and ATP indicates that formation of the
repressor complex is highly sensitive to biotin, and the
Km for ATP is in the low millimolar range (4, 29,
41). In contrast, BPLs from biotin auxotrophic species generally bind
ATP at lower concentrations, with Km values in the
range of 0.38-200 µM (42-45). The value of 21 µM reported here for S. cerevisiae is well
below the intracellular concentration of ATP (46) and is consistent
with the absence of repressor function in the eukaryotic BPLs.
The formation of an activated enzyme-bound biotinyl intermediate in the
first partial reaction of BPL requires a nucleotide triphosphate and a
divalent metal ion (34). BPLs from different organisms differ in their
specificity for both the NTP source and the divalent metal. For
example, magnesium is the preferred metal ion for pea BPL (21), whereas
zinc and manganese ions can readily substitute for magnesium ions for
the P. shermanii enzyme (6, 7). For the yeast enzyme,
calcium or magnesium ions were the preferred divalent metals, with
reasonable levels of activity also seen in the presence of nickel or
manganese, while cobalt, zinc, and copper ions failed to support
significant activity. Yeast BPL had an absolute requirement for ATP,
since only minimal enzyme activity was detected when ATP was replaced by other nucleotide triphosphates. This is similar to BPLs from P. shermanii, B. stearothermophilus, pig, and
rabbit, which are also specific for ATP (7, 8, 34, 42). However, UTP
can replace ATP for the enzyme from chicken liver (43, 47), whereas CTP
is the preferred nucleotide for both the pea (21) and bovine liver (44)
biotin ligases.
Kinetic studies on BPLs have reported a wide range of
Km values for biotin, ranging from 4.7 nM for the rabbit liver enzyme (42) to 3.3 µM
in chicken liver (43). Here we observed a low Km for
biotin (67 nM) for yeast BPL. Bakers' yeast is auxotrophic
for biotin, which is actively transported into the cell via the
recently cloned H+-biotin symporter, VHT1 (48). This
membrane-bound transport protein displays maximal activity when cells
are grown in media containing an extremely low concentration of biotin,
0.8 nM and is inhibited by greater than 8 nM
biotin (48). Rogers and Lichstein (49) demonstrated that the cellular
concentration of free biotin in yeast can be increased against a
concentration gradient. Under conditions that give maximal growth, the
free biotin pool can reach a concentration of 70 µM (49),
which would be saturating for yBPL. The mechanism of transport
inhibition is not understood, and the possibility that yBPL interacts
with the receptor to regulate biotin metabolism in yeast is both
speculative and interesting.
An upper limit for the bimolecular rate constant for the formation of
the enzyme-biotin complex can be determined using the values obtained
in the kinetic analysis. The calculated
kcat/Km value for biotin of
6.0 ± 0.08 × 106 M 1
s 1 is several orders of magnitude smaller than that
predicted for a diffusion-controlled process. This value is 3-fold
smaller than that of BirA (50) but 10-fold larger than the value
determined for A. thaliana BPL (20), suggesting subtle
structural differences in the active sites of these BPLs. yBPL was
found to be highly specific for binding biotin, since several closely
related biotin analogues and lipoic acid all failed to inhibit the
incorporation of biotin even when present at a 100-fold excess over
[3H]biotin. This substrate specificity is a common
feature of BPLs from a variety of sources (6, 21, 44). Thus, the
decreased activity of biotin-dependent enzymes in rat liver
seen after the administration of lipoic acid (51) seems unlikely to be
due to a direct effect of lipoic acid on BPL in vivo.
We have used two isolated domains as the biotin acceptor domain in our
analysis of yBPL, yPC-104, and BCCP-87. This latter peptide has been
shown to be as effective a substrate for biotinylation by BirA as
intact BCCP (52), with a Km of 4 µM in
our assay system (29). In the present study, a similarly low
Km value was determined when a yeast biotin domain
was assayed with yBPL (1 µM). However, we observed a
greater than 10-fold higher Km (11 µM)
when BCCP-87 was the substrate for yBPL. There is evidence of
cross-species reactivity in biotinylation reactions (13-15), but
kinetic analysis of the interactions has not been previously performed.
It seems likely that the differences in Km for the
two acceptor proteins for yBPL reflects subtle changes in substrate
recognition or efficiency of biotin transfer between the two proteins
in the assay system.
 |
ACKNOWLEDGEMENTS |
We thank Denise Turner for assistance with
protein sequencing, members of the 1998 Biochemistry III class for
contributions to the domain mapping and complementation assays, and
Prof. John Cronan, both for providing vectors and strains and for
continuing interest in the project.
 |
FOOTNOTES |
*
This work was supported by Australian Research Council Grant
A09531996 (to J. C. W.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Biochemistry,
University of Adelaide, Adelaide, SA 5005, Australia. Tel.: 61-8-8303-5218; Fax: 61-8-8303-4348; E-mail:
jwallace@biochem.adelaide.edu.au.
 |
ABBREVIATIONS |
The abbreviations used are:
BPL, biotin protein
ligase;
yBPL, yeast BPL;
BCCP, biotin carboxyl carrier protein;
NTA, nitrilotriacetic acid;
bp, base pair(s);
PAGE, polyacrylamide gel
electrophoresis.
 |
REFERENCES |
| 1.
|
Samols, D.,
Thornton, C. G.,
Murtif, V. L.,
Kumar, G. K.,
Haase, F. C.,
and Wood, H. G.
(1988)
J. Biol. Chem.
263,
6461-6464[Free Full Text]
|
| 2.
|
Knowles, J. R.
(1989)
Annu. Rev. Biochem.
58,
195-221[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Cronan, J. E., Jr.
(1989)
Cell
58,
427-429[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Beckett, D.,
and Matthews, B. W.
(1997)
Methods Enzymol.
279,
362-376[Medline]
[Order article via Infotrieve]
|
| 5.
|
Wilson, K. P.,
Shewchuk, L. M.,
Brennan, R. G.,
Otsuka, A. J.,
and Matthews, B. W.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
9257-9261[Abstract/Free Full Text]
|
| 6.
|
Lane, D. M.,
Young, D. L.,
and Lynen, F.
(1964)
J. Biol. Chem.
239,
2858-2864[Free Full Text]
|
| 7.
|
Shenoy, B. C.,
and Wood, H. G.
(1988)
FASEB J.
2,
2396-2401[Abstract]
|
| 8.
|
Cazzulo, J. J.,
Sundaram, T. K.,
Dilks, S. N.,
and Kornberg, H. L.
(1971)
Biochem. J.
122,
653-661[Medline]
[Order article via Infotrieve]
|
| 9.
|
Dombrosky, P. M.,
Schmid, M. B.,
and Young, K. D.
(1994)
Arch. Microbiol.
161,
501-507[Medline]
[Order article via Infotrieve]
|
| 10.
|
Bower, S.,
Perkins, J.,
Yocum, R. R.,
Serror, P.,
Sorokin, A.,
Rahaim, P.,
Howitt, C. L.,
Prasad, N.,
Ehrlich, S. D.,
and Pero, J.
(1995)
J. Bacteriol.
177,
2572-2575[Abstract/Free Full Text]
|
| 11.
|
Bult, C. J.,
White, O.,
Olsen, G. J.,
Zhou, L.,
Fleischmann, R. D.,
Sutton, G. G.,
Blake, J. A.,
FitzGerald, L. M.,
Clayton, R. A.,
Gocayne, J. D.,
Kerlavage, A. R.,
Dougherty, B. A.,
Tomb, J. F.,
Adams, M. D.,
Reich, C. I.,
Overbeek, R.,
Kirkness, E. F.,
Weinstock, K. G.,
Merrick, J. M.,
Glodek, A.,
Scott, J. L.,
Geoghagen, N. S.,
Weidman, J. F.,
Fuhrmann, J. L.,
Nguyen, D.,
Utterback, T. R.,
Kelley, J. M.,
Pererson, J. D.,
Sadow, P. W.,
Hanna, M. C.,
Cotton, M. D.,
Roberts, K. M.,
Hurst, M. A.,
Kaine, B. P.,
Borodovsky, M.,
Klenk, H.-P.,
Fraser, C. M.,
Smith, H. O.,
Woese, C. R.,
and Venter, J. C.
(1996)
Science
273,
1058-1073[Abstract]
|
| 12.
|
Klenk, H.-P.,
Clayton, R. A.,
Tomb, J.-F.,
White, O.,
Nelson, K. E.,
Ketchum, K. A.,
Dodson, R. J.,
Gwinn, M.,
Hickey, E. K.,
Peterson, J. D.,
Richardson, D. L.,
Kerlavage, A. R.,
Graham, D. E.,
Kyrpides, N. C.,
Fleischmann, R. D.,
Quackenbush, J.,
Lee, N. H.,
Sutton, G. G.,
Gill, S.,
Kirkness, E. F.,
Dougherty, B. A.,
McKenney, K.,
Adams, M. D.,
Loftus, B.,
Peterson, S.,
Reich, C. I.,
NcNeil, K.,
Badger, J. H.,
Glodek, A.,
Zhou, L.,
Overbeek, R.,
Gocayne, J. D.,
Weidman, J. F.,
McDonald, L.,
Utterback, T.,
Cotton, M. D.,
Spriggs, T.,
Artiach, P.,
Kaine, B. P.,
Sykes, S. M.,
Sadow, P. W.,
D'Andrea, K. P.,
Bowman, C.,
Fulii, C.,
Garland, S. A.,
Mason, T. M.,
Olsen, G. J.,
Fraser, C. M.,
Smith, H. O.,
Woese, C, R.,
and Venter, J. C.
(1997)
Nature
390,
364-370[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
McAllister, H. C.,
and Coon, M. J.
(1966)
J. Biol. Chem.
241,
2855-2861[Abstract/Free Full Text]
|
| 14.
|
Cronan, J. E., Jr.
(1990)
J. Biol. Chem.
265,
10327-10333[Abstract/Free Full Text]
|
| 15.
|
Leon-Del-Rio, A.,
Leclerc, D.,
Akerman, B.,
Wakamatsu, N.,
and Gravel, R. A.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
4626-4630[Abstract/Free Full Text]
|
| 16.
|
Tissot, G.,
Douce, R.,
and Alban, C.
(1997)
Biochem. J.
323,
179-188
|
| 17.
|
Chapman-Smith, A.,
and Cronan, J. E.
(1999)
J. Nutr.
129 (suppl.),
477-484[Abstract/Free Full Text]
|
| 18.
|
Cronan, J. E. J.,
and Wallace, J. C.
(1995)
FEMS Microbiol. Lett.
130,
221-229[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Suzuki, Y.,
Aoki, Y.,
Ishida, Y.,
Chiba, Y.,
Iwamatsu, A.,
Kishino, T.,
Niikawa, N.,
Matsubara, Y.,
and Narisawa, K.
(1994)
Nat. Genet.
8,
122-128[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Tissot, G.,
Pepin, R.,
Job, D.,
Douce, R.,
and Alban, C.
(1998)
Eur. J. Biochem.
258,
586-596[Medline]
[Order article via Infotrieve]
|
| 21.
|
Tissot, G.,
Job, D.,
Douce, R.,
and Alban, C.
(1996)
Biochem. J.
314,
391-395
|
| 22.
|
Dupuis, L.,
Leondelrio, A.,
Leclerc, D.,
Campeau, E.,
Sweetman, L.,
Saudubray, J. M.,
Herman, G.,
Gibson, K. M.,
and Gravel, R. A.
(1996)
Hum. Mol. Genet.
5,
1011-1016[Abstract/Free Full Text]
|
| 23.
|
Aoki, Y.,
Suzuki, Y.,
Li, X.,
Sakamoto, O.,
Chikaoka, H.,
Takita, S.,
and Narisawa, K.
(1997)
Pediatr. Res.
42,
849-854[Medline]
[Order article via Infotrieve]
|
| 24.
|
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual
, 2nd Ed.
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 25.
|
Cagnon, C.,
Valverde, V.,
and Masson, J.-M.
(1991)
Protein Eng.
4,
843-847[Abstract/Free Full Text]
|
| 26.
|
Chapman-Smith, A.,
Turner, D. L.,
Cronan, J. E.,
Morris, T. W.,
and Wallace, J. C.
(1994)
Biochem. J.
302,
881-887
|
| 27.
|
Barker, D. F.,
and Campbell, A. M.
(1981)
J. Mol. Biol.
146,
469-492[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Val, D. L.,
Chapman-Smith, A.,
Walker, M. E.,
Cronan, J. E.,
and Wallace, J. C.
(1995)
Biochem. J.
312,
817-825
|
| 29.
|
Chapman-Smith, A.,
Morris, T. W.,
Wallace, J. C.,
and Cronan, J. E., Jr.
(1999)
J. Biol. Chem.
274,
1449-1457[Abstract/Free Full Text]
|
| 30.
|
Lee, H. J.,
and Wilson, I. B.
(1971)
Biochim. Biophys. Acta
242,
519-522[Medline]
[Order article via Infotrieve]
|
| 31.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Matsudaira, P.
(1988)
J. Biol. Chem.
262,
10035-10038[Abstract/Free Full Text]
|
| 33.
|
Cleland, W. W.
(1970)
Enzymes
2,
1-65
|
| 34.
|
Christner, J. E.,
Schlesinger, M.,
and Coon, M. J.
(1964)
J. Biol. Chem.
239,
3997-4005[Free Full Text]
|
| 35.
|
Morita, J.,
Thuy, L. P.,
and Sweetman, L.
(1998)
Mol. Gen. Metab.
64,
250-255[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Xu, Y.,
and Beckett, D.
(1996)
Biochemistry
35,
1783-1792[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Xu, Y.,
Nenortas, E.,
and Beckett, D.
(1995)
Biochemistry
34,
16624-16631[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Eisenberg, M. A.,
Prakash, O.,
and Hsiung, S. C.
(1982)
J. Biol. Chem.
239,
2858-2864
|
| 39.
|
Buoncristiani, M. R.,
and Otsuka, A. J.
(1988)
J. Biol. Chem.
263,
1013-1016[Abstract/Free Full Text]
|
| 40.
|
Sundaram, T. K.,
Cazzulo, J. J.,
and Kornberg, H. L.
(1971)
Arch. Biochem. Biophys.
143,
609-616[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Xu, Y.,
and Beckett, D.
(1994)
Biochemistry
33,
7354-7360[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Siegel, L.,
Foote, J. L.,
and Coon, M. J.
(1965)
J. Biol. Chem.
240,
1025-1031[Free Full Text]
|
| 43.
|
Murthy, P. N. A.,
and Mistry, S. P.
(1974)
Can. J. Biochem.
52,
800-803[Medline]
[Order article via Infotrieve]
|
| 44.
|
Chiba, Y.,
Suzuki, Y.,
Aoki, Y.,
Ishida, Y.,
and Narisawa, K.
(1994)
Arch. Biochem. Biophys.
313,
8-14[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Xia, W.-L.,
Zhang, J.,
and Ahmad, F.
(1994)
Biochem. Mol. Biol. Int.
34,
225-232[Medline]
[Order article via Infotrieve]
|
| 46.
|
Wallace, P. G.,
Pedler, S. M.,
Wallace, J. C.,
and Berry, M. N.
(1994)
Anal. Biochem.
222,
404-408[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Madappally, M. M.,
and Mistry, S. P.
(1970)
Biochim. Biophys. Acta
215,
316-322[Medline]
[Order article via Infotrieve]
|
| 48.
|
Stolz, J.,
Hoja, U.,
Meier, S.,
Sauer, N.,
and Schweizer, E.
(1999)
J. Biol. Chem.
274,
18741-18746[Abstract/Free Full Text]
|
| 49.
|
Rogers, T. O.,
and Lichstein, H. C.
(1969)
J. Bacteriol.
100,
557-564[Abstract/Free Full Text]
|
| 50.
|
Xu, Y.,
and Beckett, D.
(1997)
Methods Enzymol.
279,
405-421[Medline]
[Order article via Infotrieve]
|
| 51.
|
Zempleni, J.,
Trusty, T. A.,
and Mock, D. M.
(1997)
J. Nutr.
127,
1776-1781[Abstract/Free Full Text]
|
| 52.
|
Nenortas, E.,
and Beckett, D.
(1996)
J. Biol. Chem.
271,
7559-7567[Abstract/Free Full Text]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
B. Bagautdinov, Y. Matsuura, S. Bagautdinova, and N. Kunishima
Protein Biotinylation Visualized by a Complex Structure of Biotin Protein Ligase with a Substrate
J. Biol. Chem.,
May 23, 2008;
283(21):
14739 - 14750.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. M. Pirner and J. Stolz
Biotin Sensing in Saccharomyces cerevisiae Is Mediated by a Conserved DNA Element and Requires the Activity of Biotin-Protein Ligase
J. Biol. Chem.,
May 5, 2006;
281(18):
12381 - 12389.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. W. Polyak, A. Chapman-Smith, T. D. Mulhern, J. E. Cronan Jr., and J. C. Wallace
Mutational Analysis of Protein Substrate Presentation in the Post-translational Attachment of Biotin to Biotin Domains
J. Biol. Chem.,
January 26, 2001;
276(5):
3037 - 3045.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Campeau and R. A. Gravel
Expression in Escherichia coli of N- and C-terminally Deleted Human Holocarboxylase Synthetase. INFLUENCE OF THE N-TERMINUS ON BIOTINYLATION AND IDENTIFICATION OF A MINIMUM FUNCTIONAL PROTEIN
J. Biol. Chem.,
April 6, 2001;
276(15):
12310 - 12316.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|